Repligen and Navigo Proteins Announce the Launch of an Affinity Resin for the Purification of COVID-19 VaccinesGlobeNewsWire • 02/08/21
Repligen Corporation to Present at 39th Annual J.P. Morgan Healthcare ConferenceGlobeNewsWire • 01/04/21
Repligen Corporation Announces Closing of Public Offering of $312.2 Million, Including Full Exercise of Underwriters' OptionGlobeNewsWire • 12/10/20
Repligen Corporation Announces Proposed Public Offering of Shares of Common StockGlobeNewsWire • 12/07/20
Why It Might Be Time To Pay Attention To These 4 Red-Hot Health StocksInvestors Business Daily • 11/13/20
Are These Medical Stocks Cruising Toward Big Gains? Here's A Bullish SignInvestors Business Daily • 11/12/20
Repligen Corporation's (RGEN) CEO Tony Hunt on Q3 2020 Results - Earnings Call TranscriptSeeking Alpha • 11/05/20
Repligen Corporation Announces Agreement to Acquire Bioprocess Systems Innovator ARTeSYN Biosolutions and Completes Acquisition of Non-Metallic SolutionsGlobeNewsWire • 10/27/20
Repligen and Navigo Proteins Announce Achievement of Key Milestone in Developing an Affinity Resin for the Purification of COVID-19 VaccinesGlobeNewsWire • 10/01/20